EMAIL THIS PAGE TO A FRIEND

The Journal of clinical psychiatry

Expected incidence of tardive dyskinesia associated with atypical antipsychotics.


PMID 10739327

Abstract

Given the problematic nature of tardive dyskinesia in persons taking conventional antipsychotics, evaluation of newer atypical antipsychotic agents should include a systematic assessment of tardive dyskinesia liability. Results of a prospective double-blind, randomized study of schizophrenic patients who participated in 3 preclinical olanzapine studies and were treated with 5 to 20 mg/day of olanzapine (N = 1192) or haloperidol (N = 522) recently indicated a significantly lower risk of development of tardive dyskinesia with olanzapine treatment than haloperidol treatment. This article discusses the known effects of atypical antipsychotic medications on tardive dyskinesia movements (both withdrawal and persistent) and the incidence rate of tardive dyskinesia among schizophrenic patients undergoing long-term treatment with olanzapine or haloperidol.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

M1818
Molindone hydrochloride, ≥98% (HPLC), solid
C16H24N2O2 · HCl